From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nizatidine structure.png
Systematic (IUPAC) name
Clinical data
Trade names Axid
AHFS/ monograph
MedlinePlus a694030
Licence data US FDA:link
Pharmacokinetic data
Bioavailability >70%
Protein binding 35%
Metabolism Hepatic
Half-life 1-2 hours
Excretion Renal
76963-41-2 YesY
PubChem CID 3033637
DrugBank DB00585 YesY
ChemSpider 2298266 YesY
KEGG D00440 YesY
Chemical data
Formula C12H21N5O2S2
331.46 g/mol
 N (what is this?)  (verify)

Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.

Clinical use[edit]

Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD), and to prevent stress ulcers.[1]

Adverse effects[edit]

Side effects are uncommon, usually minor, and include diarrhea, constipation, fatigue, drowsiness, headache, and muscle aches.[1]

History and development[edit]

Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole ring in place of the furan ring in ranitidine. In September 2000, Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals. [2] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA). [3] However, a year later, they sold rights of the Axid Oral Solution (including the issued patent US6,930,119 protecting the product) to Braintree Laboratories.[4]

Nizatidine proved to be the last new histamine H2-receptor antagonist introduced prior to the advent of proton pump inhibitors.

See also[edit]

  • Famotidine, Pepcid AC, Pepcidine: another popular H2-receptor antagonist


External links[edit]